30,900-sq.-ft. facility in Princeton, NJ houses 16 suites for cGMP product production, and labs for analytical, quality control and microbiology testing.
Acquires facility in Oxfordshire and will invest up to $160 million to complete and equip it with state-of-the-art capabilities for biologics and vaccines.
Expansion in large-scale isolator units at Malvern and Dartford, UK facilities to provide advanced containment capabilities for highly potent drug compounds.
Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.
The 24,000-sq.-ft. facility was established to support integrated development, clinical packaging, and distribution solutions for Phase 1-3 clinical studies.
Will house 18 CGMP viral vector manufacturing suites designed to accommodate multiple bioreactors up to 2,000-liter scale and commercial manufacturing.
Initial phase includes installation of two 2,000-liter single-use bioreactors and associated investments to support early-and late-phase clinical development.
Catalent to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs.